FTY720 (Fingolimod) Sensitizes Prostate Cancer Cells to Radiotherapy by Inhibition of Sphingosine Kinase-1
Dmitri Pchejetski(University of East Anglia), Olivier Cuvillier(Centre National de la Recherche Scientifique), Bernard Malavaud(Université Toulouse III - Paul Sabatier), Justin Teissié(Centre National de la Recherche Scientifique), Vishal A. Salunkhe(Lund University), N. Doumerc(Hôpital Rangueil), Jonathan Waxman(Centre National de la Recherche Scientifique), Torsten Böhler(Charité - Universitätsmedizin Berlin), Leyre Brizuela(Centre National de la Recherche Scientifique), Lysann Sauer(Centre National de la Recherche Scientifique), Muriel Golzio(Centre National de la Recherche Scientifique)
Cited by 146
Related Papers
Recommendations guidelines on the key information to be reported in studies of application of PEF technology in food and biotechnological processes
|Innovative Food Science & Emerging Technologies|2016|296
Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity
|Nature Communications|2016|287
Sphingosine Kinase-1 as a Chemotherapy Sensor in Prostate Adenocarcinoma Cell and Mouse Models
|Cancer Research|2005|203
Oxidative Stress–Dependent Sphingosine Kinase-1 Inhibition Mediates Monoamine Oxidase A–Associated Cardiac Cell Apoptosis
|Circulation Research|2006|197
The emerging role of FTY720 (Fingolimod) in cancer treatment
|Oncotarget|2016|174